Ingenia Therapeutics expects USD 5 million MK-8748 milestone payment from Merck unit Eyebiotech

Bitget2026/09/28 08:32

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Ingenia Therapeutics expects to receive a milestone payment tied to MK-8748, licensed to Merck unit Eyebiotech in 2022.
Payment amount set at USD 5 million, triggered by the start of a global Phase 3 trial in diabetic macular edema.
Invoice issued on Sept. 25, 2026, marking the milestone confirmation date under the license agreement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ingenia Therapeutics Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20260928900639), on September 28, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Ingenia Therapeutics expects USD 5 million MK-8748 milestone payment from Merck unit Eyebiotech

You may also like

Crypto prices